cgrp inhibitor cgrp8–37  (Millipore)

Journal: Biomedical Reports

Article Title: Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway

doi: 10.3892/br.2016.658

Figure Lengend Snippet: Effects of CGRP on the neurobehavioral scores of rats with focal cerebral ischemia.

Article Snippet: The reagents, including CGRP, the CGRP inhibitor CGRP8–37, the ERK inhibitor PD98059, and the p38 inhibitor SB203580, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Techniques:

Journal: Biomedical Reports

Article Title: Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway

doi: 10.3892/br.2016.658

Figure Lengend Snippet: TTC staining in all the treatment groups. Normal tissues were a pink or red color, whereas the ischemic tissues were white. Compared to the sham group, the white area of TTC staining in the brain tissues in the MCAO group significantly increased. Compared to the MCAO group, the white area in the MCAO+CGRP group significantly decreased. Compared to the MCAO+CGRP group, the white area in the MCAO+CGRP+CGRP8–37, MCAO+CGRP+PD9805 and MCAO+CGRP+SB203580 groups significantly increased. TTC, 2,3,5-triphenyltetrazolium chloride; CGRP, calcitonin gene-related peptide; MCAO, middle cerebral artery occlusion.

Article Snippet: The reagents, including CGRP, the CGRP inhibitor CGRP8–37, the ERK inhibitor PD98059, and the p38 inhibitor SB203580, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Techniques: Staining

Journal: Biomedical Reports

Article Title: Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway

doi: 10.3892/br.2016.658

Figure Lengend Snippet: Effects of CGRP on the cerebral infarction area of rats with focal cerebral ischemia.

Article Snippet: The reagents, including CGRP, the CGRP inhibitor CGRP8–37, the ERK inhibitor PD98059, and the p38 inhibitor SB203580, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Techniques:

Journal: Biomedical Reports

Article Title: Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway

doi: 10.3892/br.2016.658

Figure Lengend Snippet: Western blotting results of p-JNK/JNK in all the treatment groups. Compared to the MCAO group, the p-JNK expression level significantly decreased in the MCAO+CGRP group; in addition, the JNK expression level did not significantly change. Compared to the MCAO+CGRP, the p-JNK expression levels in the MCAO+CGRP+CGRP8–37, MCAO+CGRP+PD98059 and MCAO+CGRP+SB203580 groups significantly increased, whereas no change in the JNK expression level was identified. The comparison between groups was considered to indicate significant differences, *P<0.05. p-JNK, phosphorylated c-Jun N-terminal kinase; CGRP, calcitonin gene-related peptide; MCAO, middle cerebral artery occlusion.

Article Snippet: The reagents, including CGRP, the CGRP inhibitor CGRP8–37, the ERK inhibitor PD98059, and the p38 inhibitor SB203580, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Techniques: Western Blot, Expressing

Journal: Biomedical Reports

Article Title: Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway

doi: 10.3892/br.2016.658

Figure Lengend Snippet: Western blotting results of p-p38/p38 in all the treatment groups. Compared with the MCAO group, the p-p38 expression level in the MCAO+CGRP group significantly decreased (P<0.05); in addition, the p38 expression level did not show a significant change. Compared to the MCAO+CGRP group, the p-p38 expression levels in the MCAO+CGRP+CGRP8–37, MCAO+CGRP+PD98059 and MCAO+CGRP+SB203580 groups significantly increased (P<0.05), whereas no significant change in the p38 protein expression levels was identified. The comparison between groups was considered to indicate significant differences, *P<0.05. CGRP, calcitonin gene-related peptide; MCAO, middle cerebral artery occlusion.

Article Snippet: The reagents, including CGRP, the CGRP inhibitor CGRP8–37, the ERK inhibitor PD98059, and the p38 inhibitor SB203580, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Techniques: Western Blot, Expressing

Journal: Biomedical Reports

Article Title: Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway

doi: 10.3892/br.2016.658

Figure Lengend Snippet: Western blotting results of p-ERK/ERK in all the treatment groups. Compared to the MCAO group, the p-ERK expression level significantly increased in the brain tissues in the MCAO+CGRP group; whereas no significant change in the ERK expression was identified. Compared to the MCAO+CGRP group, the expression level of the p-ERK significantly decreased in the MCAO+CGRP+CGRP8–37, MCAO+CGRP+PD98059 and MCAO+CGRP+SB203580 groups; the largest reduction was evident in the MCAO+CGRP+PD98059 group, whereas no significant change in the expression level of the ERK protein was observed. The comparison between groups was considered to indicate significant differences, *P<0.05 and **P<0.01. CGRP, calcitonin gene-related peptide; MCAO, middle cerebral artery occlusion.

Article Snippet: The reagents, including CGRP, the CGRP inhibitor CGRP8–37, the ERK inhibitor PD98059, and the p38 inhibitor SB203580, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Techniques: Western Blot, Expressing